A PHP Error was encountered

Severity: Warning

Message: fopen(/var/cpanel/php/sessions/ea-php72/ci_session5860f6b1806dbe0ca73a0010835b0934a8229cb0): failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 176

Backtrace:

File: /home/rejovjcx/mraccuracyreports.com/application/controllers/Reportdetails.php
Line: 10
Function: library

File: /home/rejovjcx/mraccuracyreports.com/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/cpanel/php/sessions/ea-php72)

Filename: Session/Session.php

Line Number: 143

Backtrace:

File: /home/rejovjcx/mraccuracyreports.com/application/controllers/Reportdetails.php
Line: 10
Function: library

File: /home/rejovjcx/mraccuracyreports.com/index.php
Line: 315
Function: require_once

Global Cellular and Gene Therapy CDMO Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application

img

Global Cellular and Gene Therapy CDMO Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application


Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Cellular and Gene Therapy CDMO Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application

Cellular and Gene Therapy CDMO report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Cellular and Gene Therapy CDMO market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Commercial and Academic Research are the major drivers for the industry.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Cellular and Gene Therapy CDMO market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report



By Company


Catalent
Lonza
Charles River
The Discovery Labs
BIOCENTRIQ
FUJIFILM Diosynth Biotechnologies
Exothera
WuXi AppTec
Pharmaron
OBiO
Cell Therapies
AGC Biologics
Cytiva
Helixmith
ThermoGenesis
Anemocyte
Thermo Fisher Scientific
CBM
Bio Elpida
Genezen
CCRM
RoslinCT
GenScript ProBio
Oxford BioMedica
Porton Pharma Solutions
Segment by Type
Cell Therapy
Viral Vectors
Plasmid

Segment by Application


Commercial
Academic Research
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia

Latin America
Mexico
Brazil

Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Cellular and Gene Therapy CDMO market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Cellular and Gene Therapy CDMO introduction, etc. Cellular and Gene Therapy CDMO Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Cellular and Gene Therapy CDMO market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.

Table of Content

1 Market Overview of Cellular and Gene Therapy CDMO
1.1 Cellular and Gene Therapy CDMO Market Overview
1.1.1 Cellular and Gene Therapy CDMO Product Scope
1.1.2 Cellular and Gene Therapy CDMO Market Status and Outlook
1.2 Global Cellular and Gene Therapy CDMO Market Size Overview by Region 2018 VS 2022 VS 2033
1.3 Global Cellular and Gene Therapy CDMO Market Size by Region (2018-2033)
1.4 Global Cellular and Gene Therapy CDMO Historic Market Size by Region (2018-2023)
1.5 Global Cellular and Gene Therapy CDMO Market Size Forecast by Region (2024-2033)
1.6 Key Regions, Cellular and Gene Therapy CDMO Market Size (2018-2033)
1.6.1 North America Cellular and Gene Therapy CDMO Market Size (2018-2033)
1.6.2 Europe Cellular and Gene Therapy CDMO Market Size (2018-2033)
1.6.3 Asia-Pacific Cellular and Gene Therapy CDMO Market Size (2018-2033)
1.6.4 Latin America Cellular and Gene Therapy CDMO Market Size (2018-2033)
1.6.5 Middle East & Africa Cellular and Gene Therapy CDMO Market Size (2018-2033)
2 Cellular and Gene Therapy CDMO Market by Type
2.1 Introduction
2.1.1 Cell Therapy
2.1.2 Viral Vectors
2.1.3 Plasmid
2.2 Global Cellular and Gene Therapy CDMO Market Size by Type: 2018 VS 2022 VS 2033
2.2.1 Global Cellular and Gene Therapy CDMO Historic Market Size by Type (2018-2023)
2.2.2 Global Cellular and Gene Therapy CDMO Forecasted Market Size by Type (2024-2033)
2.3 Key Regions Market Size by Type
2.3.1 North America Cellular and Gene Therapy CDMO Revenue Breakdown by Type (2018-2033)
2.3.2 Europe Cellular and Gene Therapy CDMO Revenue Breakdown by Type (2018-2033)
2.3.3 Asia-Pacific Cellular and Gene Therapy CDMO Revenue Breakdown by Type (2018-2033)
2.3.4 Latin America Cellular and Gene Therapy CDMO Revenue Breakdown by Type (2018-2033)
2.3.5 Middle East and Africa Cellular and Gene Therapy CDMO Revenue Breakdown by Type (2018-2033)
3 Cellular and Gene Therapy CDMO Market Overview by Application
3.1 Introduction
3.1.1 Commercial
3.1.2 Academic Research
3.1.3 Others
3.2 Global Cellular and Gene Therapy CDMO Market Size by Application: 2018 VS 2022 VS 2033
3.2.1 Global Cellular and Gene Therapy CDMO Historic Market Size by Application (2018-2023)
3.2.2 Global Cellular and Gene Therapy CDMO Forecasted Market Size by Application (2024-2033)
3.3 Key Regions Market Size by Application
3.3.1 North America Cellular and Gene Therapy CDMO Revenue Breakdown by Application (2018-2033)
3.3.2 Europe Cellular and Gene Therapy CDMO Revenue Breakdown by Application (2018-2033)
3.3.3 Asia-Pacific Cellular and Gene Therapy CDMO Revenue Breakdown by Application (2018-2033)
3.3.4 Latin America Cellular and Gene Therapy CDMO Revenue Breakdown by Application (2018-2033)
3.3.5 Middle East and Africa Cellular and Gene Therapy CDMO Revenue Breakdown by Application (2018-2033)
4 Cellular and Gene Therapy CDMO Competition Analysis by Players
4.1 Global Cellular and Gene Therapy CDMO Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Cellular and Gene Therapy CDMO as of 2022)
4.3 Date of Key Players Enter into Cellular and Gene Therapy CDMO Market
4.4 Global Top Players Cellular and Gene Therapy CDMO Headquarters and Area Served
4.5 Key Players Cellular and Gene Therapy CDMO Product Solution and Service
4.6 Competitive Status
4.6.1 Cellular and Gene Therapy CDMO Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Catalent
5.1.1 Catalent Profile
5.1.2 Catalent Main Business
5.1.3 Catalent Cellular and Gene Therapy CDMO Products, Services and Solutions
5.1.4 Catalent Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.1.5 Catalent Recent Developments
5.2 Lonza
5.2.1 Lonza Profile
5.2.2 Lonza Main Business
5.2.3 Lonza Cellular and Gene Therapy CDMO Products, Services and Solutions
5.2.4 Lonza Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.2.5 Lonza Recent Developments
5.3 Charles River
5.3.1 Charles River Profile
5.3.2 Charles River Main Business
5.3.3 Charles River Cellular and Gene Therapy CDMO Products, Services and Solutions
5.3.4 Charles River Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.3.5 The Discovery Labs Recent Developments
5.4 The Discovery Labs
5.4.1 The Discovery Labs Profile
5.4.2 The Discovery Labs Main Business
5.4.3 The Discovery Labs Cellular and Gene Therapy CDMO Products, Services and Solutions
5.4.4 The Discovery Labs Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.4.5 The Discovery Labs Recent Developments
5.5 BIOCENTRIQ
5.5.1 BIOCENTRIQ Profile
5.5.2 BIOCENTRIQ Main Business
5.5.3 BIOCENTRIQ Cellular and Gene Therapy CDMO Products, Services and Solutions
5.5.4 BIOCENTRIQ Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.5.5 BIOCENTRIQ Recent Developments
5.6 FUJIFILM Diosynth Biotechnologies
5.6.1 FUJIFILM Diosynth Biotechnologies Profile
5.6.2 FUJIFILM Diosynth Biotechnologies Main Business
5.6.3 FUJIFILM Diosynth Biotechnologies Cellular and Gene Therapy CDMO Products, Services and Solutions
5.6.4 FUJIFILM Diosynth Biotechnologies Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.6.5 FUJIFILM Diosynth Biotechnologies Recent Developments
5.7 Exothera
5.7.1 Exothera Profile
5.7.2 Exothera Main Business
5.7.3 Exothera Cellular and Gene Therapy CDMO Products, Services and Solutions
5.7.4 Exothera Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.7.5 Exothera Recent Developments
5.8 WuXi AppTec
5.8.1 WuXi AppTec Profile
5.8.2 WuXi AppTec Main Business
5.8.3 WuXi AppTec Cellular and Gene Therapy CDMO Products, Services and Solutions
5.8.4 WuXi AppTec Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.8.5 WuXi AppTec Recent Developments
5.9 Pharmaron
5.9.1 Pharmaron Profile
5.9.2 Pharmaron Main Business
5.9.3 Pharmaron Cellular and Gene Therapy CDMO Products, Services and Solutions
5.9.4 Pharmaron Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.9.5 Pharmaron Recent Developments
5.10 OBiO
5.10.1 OBiO Profile
5.10.2 OBiO Main Business
5.10.3 OBiO Cellular and Gene Therapy CDMO Products, Services and Solutions
5.10.4 OBiO Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.10.5 OBiO Recent Developments
5.11 Cell Therapies
5.11.1 Cell Therapies Profile
5.11.2 Cell Therapies Main Business
5.11.3 Cell Therapies Cellular and Gene Therapy CDMO Products, Services and Solutions
5.11.4 Cell Therapies Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.11.5 Cell Therapies Recent Developments
5.12 AGC Biologics
5.12.1 AGC Biologics Profile
5.12.2 AGC Biologics Main Business
5.12.3 AGC Biologics Cellular and Gene Therapy CDMO Products, Services and Solutions
5.12.4 AGC Biologics Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.12.5 AGC Biologics Recent Developments
5.13 Cytiva
5.13.1 Cytiva Profile
5.13.2 Cytiva Main Business
5.13.3 Cytiva Cellular and Gene Therapy CDMO Products, Services and Solutions
5.13.4 Cytiva Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.13.5 Cytiva Recent Developments
5.14 Helixmith
5.14.1 Helixmith Profile
5.14.2 Helixmith Main Business
5.14.3 Helixmith Cellular and Gene Therapy CDMO Products, Services and Solutions
5.14.4 Helixmith Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.14.5 Helixmith Recent Developments
5.15 ThermoGenesis
5.15.1 ThermoGenesis Profile
5.15.2 ThermoGenesis Main Business
5.15.3 ThermoGenesis Cellular and Gene Therapy CDMO Products, Services and Solutions
5.15.4 ThermoGenesis Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.15.5 ThermoGenesis Recent Developments
5.16 Anemocyte
5.16.1 Anemocyte Profile
5.16.2 Anemocyte Main Business
5.16.3 Anemocyte Cellular and Gene Therapy CDMO Products, Services and Solutions
5.16.4 Anemocyte Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.16.5 Anemocyte Recent Developments
5.17 Thermo Fisher Scientific
5.17.1 Thermo Fisher Scientific Profile
5.17.2 Thermo Fisher Scientific Main Business
5.17.3 Thermo Fisher Scientific Cellular and Gene Therapy CDMO Products, Services and Solutions
5.17.4 Thermo Fisher Scientific Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.17.5 Thermo Fisher Scientific Recent Developments
5.18 CBM
5.18.1 CBM Profile
5.18.2 CBM Main Business
5.18.3 CBM Cellular and Gene Therapy CDMO Products, Services and Solutions
5.18.4 CBM Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.18.5 CBM Recent Developments
5.19 Bio Elpida
5.19.1 Bio Elpida Profile
5.19.2 Bio Elpida Main Business
5.19.3 Bio Elpida Cellular and Gene Therapy CDMO Products, Services and Solutions
5.19.4 Bio Elpida Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.19.5 Bio Elpida Recent Developments
5.20 Genezen
5.20.1 Genezen Profile
5.20.2 Genezen Main Business
5.20.3 Genezen Cellular and Gene Therapy CDMO Products, Services and Solutions
5.20.4 Genezen Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.20.5 Genezen Recent Developments
5.21 CCRM
5.21.1 CCRM Profile
5.21.2 CCRM Main Business
5.21.3 CCRM Cellular and Gene Therapy CDMO Products, Services and Solutions
5.21.4 CCRM Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.21.5 CCRM Recent Developments
5.22 RoslinCT
5.22.1 RoslinCT Profile
5.22.2 RoslinCT Main Business
5.22.3 RoslinCT Cellular and Gene Therapy CDMO Products, Services and Solutions
5.22.4 RoslinCT Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.22.5 RoslinCT Recent Developments
5.23 GenScript ProBio
5.23.1 GenScript ProBio Profile
5.23.2 GenScript ProBio Main Business
5.23.3 GenScript ProBio Cellular and Gene Therapy CDMO Products, Services and Solutions
5.23.4 GenScript ProBio Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.23.5 GenScript ProBio Recent Developments
5.24 Oxford BioMedica
5.24.1 Oxford BioMedica Profile
5.24.2 Oxford BioMedica Main Business
5.24.3 Oxford BioMedica Cellular and Gene Therapy CDMO Products, Services and Solutions
5.24.4 Oxford BioMedica Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.24.5 Oxford BioMedica Recent Developments
5.25 Porton Pharma Solutions
5.25.1 Porton Pharma Solutions Profile
5.25.2 Porton Pharma Solutions Main Business
5.25.3 Porton Pharma Solutions Cellular and Gene Therapy CDMO Products, Services and Solutions
5.25.4 Porton Pharma Solutions Cellular and Gene Therapy CDMO Revenue (US$ Million) & (2018-2023)
5.25.5 Porton Pharma Solutions Recent Developments
6 North America
6.1 North America Cellular and Gene Therapy CDMO Market Size by Country (2018-2033)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Cellular and Gene Therapy CDMO Market Size by Country (2018-2033)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Cellular and Gene Therapy CDMO Market Size by Region (2018-2033)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Cellular and Gene Therapy CDMO Market Size by Country (2018-2033)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Cellular and Gene Therapy CDMO Market Size by Country (2018-2033)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Cellular and Gene Therapy CDMO Market Dynamics
11.1 Cellular and Gene Therapy CDMO Industry Trends
11.2 Cellular and Gene Therapy CDMO Market Drivers
11.3 Cellular and Gene Therapy CDMO Market Challenges
11.4 Cellular and Gene Therapy CDMO Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Cellular and Gene Therapy CDMO Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2033
Table 2. Global Cellular and Gene Therapy CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 3. Global Cellular and Gene Therapy CDMO Market Size Share by Region (2018-2023)
Table 4. Global Cellular and Gene Therapy CDMO Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 5. Global Cellular and Gene Therapy CDMO Forecasted Market Size Share by Region (2024-2033)
Table 6. Global Cellular and Gene Therapy CDMO Market Size (US$ Million) by Type: 2018 VS 2022 VS 2033
Table 7. Global Cellular and Gene Therapy CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 8. Global Cellular and Gene Therapy CDMO Revenue Market Share by Type (2018-2023)
Table 9. Global Cellular and Gene Therapy CDMO Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 10. Global Cellular and Gene Therapy CDMO Revenue Market Share by Type (2024-2033)
Table 11. North America Cellular and Gene Therapy CDMO Revenue by Type (2018-2023) & (US$ Million)
Table 12. North America Cellular and Gene Therapy CDMO Revenue by Type (2024-2033) & (US$ Million)
Table 13. Europe Cellular and Gene Therapy CDMO Revenue by Type (2018-2023) & (US$ Million)
Table 14. Europe Cellular and Gene Therapy CDMO Revenue by Type (2024-2033) & (US$ Million)
Table 15. Asia-Pacific Cellular and Gene Therapy CDMO Revenue by Type (2018-2023) & (US$ Million)
Table 16. Asia-Pacific Cellular and Gene Therapy CDMO Revenue by Type (2024-2033) & (US$ Million)
Table 17. Latin America Cellular and Gene Therapy CDMO Revenue by Type (2018-2023) & (US$ Million)
Table 18. Latin America Cellular and Gene Therapy CDMO Revenue by Type (2024-2033) & (US$ Million)
Table 19. Middle East and Africa Cellular and Gene Therapy CDMO Revenue by Type (2018-2023) & (US$ Million)
Table 20. Middle East and Africa Cellular and Gene Therapy CDMO Revenue by Type (2024-2033) & (US$ Million)
Table 21. Global Cellular and Gene Therapy CDMO Market Size (US$ Million) by Application: 2018 VS 2022 VS 2033
Table 22. Global Cellular and Gene Therapy CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 23. Global Cellular and Gene Therapy CDMO Revenue Market Share by Application (2018-2023)
Table 24. Global Cellular and Gene Therapy CDMO Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 25. Global Cellular and Gene Therapy CDMO Revenue Market Share by Application (2024-2033)
Table 26. North America Cellular and Gene Therapy CDMO Revenue by Application (2018-2023) & (US$ Million)
Table 27. North America Cellular and Gene Therapy CDMO Revenue by Application (2024-2033) & (US$ Million)
Table 28. Europe Cellular and Gene Therapy CDMO Revenue by Application (2018-2023) & (US$ Million)
Table 29. Europe Cellular and Gene Therapy CDMO Revenue by Application (2024-2033) & (US$ Million)
Table 30. Asia-Pacific Cellular and Gene Therapy CDMO Revenue by Application (2018-2023) & (US$ Million)
Table 31. Asia-Pacific Cellular and Gene Therapy CDMO Revenue by Application (2024-2033) & (US$ Million)
Table 32. Latin America Cellular and Gene Therapy CDMO Revenue by Application (2018-2023) & (US$ Million)
Table 33. Latin America Cellular and Gene Therapy CDMO Revenue by Application (2024-2033) & (US$ Million)
Table 34. Middle East and Africa Cellular and Gene Therapy CDMO Revenue by Application (2018-2023) & (US$ Million)
Table 35. Middle East and Africa Cellular and Gene Therapy CDMO Revenue by Application (2024-2033) & (US$ Million)
Table 36. Global Cellular and Gene Therapy CDMO Revenue (US$ Million) by Players (2018-2023)
Table 37. Global Cellular and Gene Therapy CDMO Revenue Market Share by Players (2018-2023)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Cellular and Gene Therapy CDMO as of 2022)
Table 39. Date of Key Players Enter into Cellular and Gene Therapy CDMO Market
Table 40. Global Cellular and Gene Therapy CDMO Key Players Headquarters and Area Served
Table 41. Cellular and Gene Therapy CDMO Product Solution and Service
Table 42. Global Cellular and Gene Therapy CDMO Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. Catalent Basic Information List
Table 45. Catalent Description and Business Overview
Table 46. Catalent Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 47. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of Catalent (2018-2023)
Table 48. Catalent Recent Developments
Table 49. Lonza Basic Information List
Table 50. Lonza Description and Business Overview
Table 51. Lonza Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 52. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of Lonza (2018-2023)
Table 53. Lonza Recent Developments
Table 54. Charles River Basic Information List
Table 55. Charles River Description and Business Overview
Table 56. Charles River Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 57. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of Charles River (2018-2023)
Table 58. Charles River Recent Developments
Table 59. The Discovery Labs Basic Information List
Table 60. The Discovery Labs Description and Business Overview
Table 61. The Discovery Labs Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 62. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of The Discovery Labs (2018-2023)
Table 63. The Discovery Labs Recent Developments
Table 64. BIOCENTRIQ Basic Information List
Table 65. BIOCENTRIQ Description and Business Overview
Table 66. BIOCENTRIQ Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 67. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of BIOCENTRIQ (2018-2023)
Table 68. BIOCENTRIQ Recent Developments
Table 69. FUJIFILM Diosynth Biotechnologies Basic Information List
Table 70. FUJIFILM Diosynth Biotechnologies Description and Business Overview
Table 71. FUJIFILM Diosynth Biotechnologies Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 72. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of FUJIFILM Diosynth Biotechnologies (2018-2023)
Table 73. FUJIFILM Diosynth Biotechnologies Recent Developments
Table 74. Exothera Basic Information List
Table 75. Exothera Description and Business Overview
Table 76. Exothera Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 77. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of Exothera (2018-2023)
Table 78. Exothera Recent Developments
Table 79. WuXi AppTec Basic Information List
Table 80. WuXi AppTec Description and Business Overview
Table 81. WuXi AppTec Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 82. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of WuXi AppTec (2018-2023)
Table 83. WuXi AppTec Recent Developments
Table 84. Pharmaron Basic Information List
Table 85. Pharmaron Description and Business Overview
Table 86. Pharmaron Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 87. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of Pharmaron (2018-2023)
Table 88. Pharmaron Recent Developments
Table 89. OBiO Basic Information List
Table 90. OBiO Description and Business Overview
Table 91. OBiO Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 92. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of OBiO (2018-2023)
Table 93. OBiO Recent Developments
Table 94. Cell Therapies Basic Information List
Table 95. Cell Therapies Description and Business Overview
Table 96. Cell Therapies Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 97. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of Cell Therapies (2018-2023)
Table 98. Cell Therapies Recent Developments
Table 99. AGC Biologics Basic Information List
Table 100. AGC Biologics Description and Business Overview
Table 101. AGC Biologics Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 102. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of AGC Biologics (2018-2023)
Table 103. AGC Biologics Recent Developments
Table 104. Cytiva Basic Information List
Table 105. Cytiva Description and Business Overview
Table 106. Cytiva Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 107. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of Cytiva (2018-2023)
Table 108. Cytiva Recent Developments
Table 109. Helixmith Basic Information List
Table 110. Helixmith Description and Business Overview
Table 111. Helixmith Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 112. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of Helixmith (2018-2023)
Table 113. Helixmith Recent Developments
Table 114. ThermoGenesis Basic Information List
Table 115. ThermoGenesis Description and Business Overview
Table 116. ThermoGenesis Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 117. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of ThermoGenesis (2018-2023)
Table 118. ThermoGenesis Recent Developments
Table 119. Anemocyte Basic Information List
Table 120. Anemocyte Description and Business Overview
Table 121. Anemocyte Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 122. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of Anemocyte (2018-2023)
Table 123. Anemocyte Recent Developments
Table 124. Thermo Fisher Scientific Basic Information List
Table 125. Thermo Fisher Scientific Description and Business Overview
Table 126. Thermo Fisher Scientific Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 127. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of Thermo Fisher Scientific (2018-2023)
Table 128. Thermo Fisher Scientific Recent Developments
Table 129. CBM Basic Information List
Table 130. CBM Description and Business Overview
Table 131. CBM Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 132. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of CBM (2018-2023)
Table 133. CBM Recent Developments
Table 134. Bio Elpida Basic Information List
Table 135. Bio Elpida Description and Business Overview
Table 136. Bio Elpida Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 137. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of Bio Elpida (2018-2023)
Table 138. Bio Elpida Recent Developments
Table 139. Genezen Basic Information List
Table 140. Genezen Description and Business Overview
Table 141. Genezen Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 142. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of Genezen (2018-2023)
Table 143. Genezen Recent Developments
Table 144. CCRM Basic Information List
Table 145. CCRM Description and Business Overview
Table 146. CCRM Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 147. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of CCRM (2018-2023)
Table 148. CCRM Recent Developments
Table 149. RoslinCT Basic Information List
Table 150. RoslinCT Description and Business Overview
Table 151. RoslinCT Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 152. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of RoslinCT (2018-2023)
Table 153. RoslinCT Recent Developments
Table 154. GenScript ProBio Basic Information List
Table 155. GenScript ProBio Description and Business Overview
Table 156. GenScript ProBio Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 157. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of GenScript ProBio (2018-2023)
Table 158. GenScript ProBio Recent Developments
Table 159. Oxford BioMedica Basic Information List
Table 160. Oxford BioMedica Description and Business Overview
Table 161. Oxford BioMedica Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 162. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of Oxford BioMedica (2018-2023)
Table 163. Oxford BioMedica Recent Developments
Table 164. Porton Pharma Solutions Basic Information List
Table 165. Porton Pharma Solutions Description and Business Overview
Table 166. Porton Pharma Solutions Cellular and Gene Therapy CDMO Products, Services and Solutions
Table 167. Revenue (US$ Million) in Cellular and Gene Therapy CDMO Business of Porton Pharma Solutions (2018-2023)
Table 168. Porton Pharma Solutions Recent Developments
Table 169. North America Cellular and Gene Therapy CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 170. North America Cellular and Gene Therapy CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 171. Europe Cellular and Gene Therapy CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 172. Europe Cellular and Gene Therapy CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 173. Asia-Pacific Cellular and Gene Therapy CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 174. Asia-Pacific Cellular and Gene Therapy CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 175. Asia-Pacific Cellular and Gene Therapy CDMO Market Size by Region (2024-2033) & (US$ Million)
Table 176. Asia-Pacific Cellular and Gene Therapy CDMO Market Share by Region (2018-2023)
Table 177. Asia-Pacific Cellular and Gene Therapy CDMO Market Share by Region (2024-2033)
Table 178. Latin America Cellular and Gene Therapy CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 179. Latin America Cellular and Gene Therapy CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 180. Latin America Cellular and Gene Therapy CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 181. Middle East & Africa Cellular and Gene Therapy CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 182. Middle East & Africa Cellular and Gene Therapy CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 183. Middle East & Africa Cellular and Gene Therapy CDMO Market Size by Country (2024-2033) & (US$ Million)
Table 184. Cellular and Gene Therapy CDMO Market Trends
Table 185. Cellular and Gene Therapy CDMO Market Drivers
Table 186. Cellular and Gene Therapy CDMO Market Challenges
Table 187. Cellular and Gene Therapy CDMO Market Restraints
Table 188. Research Programs/Design for This Report
Table 189. Key Data Information from Secondary Sources
Table 190. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Cellular and Gene Therapy CDMO Market Size Year-over-Year 2018-2033 & (US$ Million)
Figure 2. Global Cellular and Gene Therapy CDMO Market Size (US$ Million), 2018 VS 2022 VS 2033
Figure 3. Global Cellular and Gene Therapy CDMO Market Share by Regions: 2022 VS 2033
Figure 4. Global Cellular and Gene Therapy CDMO Forecasted Market Size Share by Region (2024-2033)
Figure 5. North America Cellular and Gene Therapy CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 6. Europe Cellular and Gene Therapy CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 7. Asia-Pacific Cellular and Gene Therapy CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 8. Latin America Cellular and Gene Therapy CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 9. Middle East & Africa Cellular and Gene Therapy CDMO Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 10. Product Picture of Cell Therapy
Figure 11. Global Cell Therapy Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 12. Product Picture of Viral Vectors
Figure 13. Global Viral Vectors Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 14. Product Picture of Plasmid
Figure 15. Global Plasmid Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 16. Global Cellular and Gene Therapy CDMO Market Size Share by Type: 2022 & 2033
Figure 17. North America Cellular and Gene Therapy CDMO Revenue Market Share by Type (2018-2033)
Figure 18. Europe Cellular and Gene Therapy CDMO Revenue Market Share by Type (2018-2033)
Figure 19. Asia-Pacific Cellular and Gene Therapy CDMO Revenue Market Share by Type (2018-2033)
Figure 20. Latin America Cellular and Gene Therapy CDMO Revenue Market Share by Type (2018-2033)
Figure 21. Middle East and Africa Cellular and Gene Therapy CDMO Revenue Market Share by Type (2018-2033)
Figure 22. Commercial Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 23. Academic Research Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 24. Others Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 25. Global Cellular and Gene Therapy CDMO Market Size Share by Application: 2022 & 2033
Figure 26. North America Cellular and Gene Therapy CDMO Revenue Market Share by Application (2018-2033)
Figure 27. Europe Cellular and Gene Therapy CDMO Revenue Market Share by Application (2018-2033)
Figure 28. Asia-Pacific Cellular and Gene Therapy CDMO Revenue Market Share by Application (2018-2033)
Figure 29. Latin America Cellular and Gene Therapy CDMO Revenue Market Share by Application (2018-2033)
Figure 30. Middle East and Africa Cellular and Gene Therapy CDMO Revenue Market Share by Application (2018-2033)
Figure 31. Cellular and Gene Therapy CDMO Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 32. Global Top 5 and Top 10 Players Cellular and Gene Therapy CDMO Market Share in 2022
Figure 33. North America Cellular and Gene Therapy CDMO Market Share by Country (2018-2033)
Figure 34. United States Cellular and Gene Therapy CDMO Market Size (2018-2033) & (US$ Million)
Figure 35. Canada Cellular and Gene Therapy CDMO Market Size (2018-2033) & (US$ Million)
Figure 36. Germany Cellular and Gene Therapy CDMO Market Size (2018-2033) & (US$ Million)
Figure 37. France Cellular and Gene Therapy CDMO Market Size (2018-2033) & (US$ Million)
Figure 38. U.K. Cellular and Gene Therapy CDMO Market Size (2018-2033) & (US$ Million)
Figure 39. Italy Cellular and Gene Therapy CDMO Market Size (2018-2033) & (US$ Million)
Figure 40. Russia Cellular and Gene Therapy CDMO Market Size (2018-2033) & (US$ Million)
Figure 41. Nordic Countries Cellular and Gene Therapy CDMO Market Size (2018-2033) & (US$ Million)
Figure 42. Asia-Pacific Cellular and Gene Therapy CDMO Market Share by Region (2018-2033)
Figure 43. China Cellular and Gene Therapy CDMO Market Size (2018-2033) & (US$ Million)
Figure 44. Japan Cellular and Gene Therapy CDMO Market Size (2018-2033) & (US$ Million)
Figure 45. South Korea Cellular and Gene Therapy CDMO Market Size (2018-2033) & (US$ Million)
Figure 46. Southeast Asia Cellular and Gene Therapy CDMO Market Size (2018-2033) & (US$ Million)
Figure 47. India Cellular and Gene Therapy CDMO Market Size (2018-2033) & (US$ Million)
Figure 48. Australia Cellular and Gene Therapy CDMO Market Size (2018-2033) & (US$ Million)
Figure 49. Latin America Cellular and Gene Therapy CDMO Market Share by Country (2018-2033)
Figure 50. Mexico Cellular and Gene Therapy CDMO Market Size (2018-2033) & (US$ Million)
Figure 51. Brazil Cellular and Gene Therapy CDMO Market Size (2018-2033) & (US$ Million)
Figure 52. Middle East & Africa Cellular and Gene Therapy CDMO Market Share by Country (2018-2033)
Figure 53. Turkey Cellular and Gene Therapy CDMO Market Size (2018-2033) & (US$ Million)
Figure 54. Saudi Arabia Cellular and Gene Therapy CDMO Market Size (2018-2033) & (US$ Million)
Figure 55. UAE Cellular and Gene Therapy CDMO Market Size (2018-2033) & (US$ Million)
Figure 56. Bottom-up and Top-down Approaches for This Report